Literature DB >> 7826830

Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.

R T van Dongen1, B J Crul, P M Koopman-Kimenai, T B Vree.   

Abstract

Concentrations of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were measured by h.p.l.c. in plasma and cerebrospinal fluid (CSF) samples from 16 patients with cancer receiving oral (controlled-release) morphine. There was a close correlation between plasma and CSF morphine concentrations (r = 0.94, P = 0.0001) and both correlated with drug dosage (r = 0.61, P = 0.013 and r = 0.74, P = 0.0001, respectively). M3G and M6G in plasma and CSF were correlated (r = 0.81 and r = 0.82, both P = 0.0001). No relationship was apparent between M plus M6G concentrations in the CSF and pain scores.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826830      PMCID: PMC1364800          DOI: 10.1111/j.1365-2125.1994.tb04352.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Oral morphine in cancer pain: influences on morphine and metabolite concentration.

Authors:  H J McQuay; D Carroll; C C Faura; D J Gavaghan; C W Hand; R A Moore
Journal:  Clin Pharmacol Ther       Date:  1990-09       Impact factor: 6.875

2.  High-performance liquid chromatography and preliminary pharmacokinetics of nicomorphine and its metabolites 3-nicotinoyl- and 6-nicotinoylmorphine and morphine.

Authors:  P M Koopman-Kimenai; T B Vree; M W Cress-Tijhuis; L H Booy; G Drijkoningen
Journal:  J Chromatogr       Date:  1987-05-15

3.  The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients.

Authors:  R W Milne; R L Nation; A A Somogyi; F Bochner; W M Griggs
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

4.  Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.

Authors:  P A Carrupt; B Testa; A Bechalany; N el Tayar; P Descas; D Perrissoud
Journal:  J Med Chem       Date:  1991-04       Impact factor: 7.446

5.  Differential effects of epidural morphine in the treatment of cancer-related pain.

Authors:  S Arnér; B Arnér
Journal:  Acta Anaesthesiol Scand       Date:  1985-01       Impact factor: 2.105

6.  Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine.

Authors:  M H Hanna; S J Peat; M Woodham; A Knibb; C Fung
Journal:  Br J Anaesth       Date:  1990-05       Impact factor: 9.166

7.  CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine.

Authors:  Håkan Samuelsson; Thomas Hedner; Richard Venn; Andrew Michalkiewicz
Journal:  Pain       Date:  1993-02       Impact factor: 6.961

8.  Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation.

Authors:  A Khojasteh; W Evans; R D Reynolds; G Thomas; J J Savarese
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

9.  Human brain metabolism of morphine and naloxone.

Authors:  Agneta Wahlström; Bengt Winblad; Marie Bixo; Anders Rane
Journal:  Pain       Date:  1988-11       Impact factor: 6.961

10.  Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.

Authors:  A A Somogyi; R L Nation; C Olweny; P Tsirgiotis; J van Crugten; R W Milne; J F Cleary; C Danz; F Bochner
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

View more
  2 in total

1.  Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.

Authors:  Ingolf Meineke; Stefan Freudenthaler; Ute Hofmann; Elke Schaeffeler; Gerd Mikus; Matthias Schwab; Hilmar W Prange; Christoph H Gleiter; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

Review 2.  Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.

Authors:  G K Gourlay
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.